Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.

“I read MedCity because it captures the pulse of what's going on in healthcare innovation, a go to source. I also like how MedCity supports women in digital health.”

Dr. Charlene Ngamwajasat, @doctorcharlene, Physician and techie

Sign up for our daily newsletter

Roche’s Actemra can now be used in earlier-stage arthritis treatment

October 12, 2012 7:19 pm by | 0 Comments

(Reuters) - Roche Holding AG said U.S. regulators have widened the approved use of rheumatoid arthritis drug Actemra to include patients typically in earlier stages of treatment for the joint disease.

Actemra was approved in early 2010 for patients who had failed treatment with a widely used class of medicines called TNF inhibitors, which include Abbott Laboratories Inc's Humira and Embrel from Amgen Inc and Pfizer Inc.

But Roche's Genentech drug unit on Friday said the U.S. Food and Drug Administration is now allowing the company to market Actemra for patients who had failed to benefit from methotrexate or other drugs typically given prior to TNF inhibitors.

In effect, Actemra can now be used as a second-line therapy, instead of as a third treatment option.


(Reporting by Ransdell Pierson and Bill Berkrot in New York; editing by Matthew Lewis)

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.